Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epaminurad PK Study in Healthy Volunteers
NCT07374406Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of epaminurad in gout (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area under the plasma concentration versus time curve at 3 days and Peak plasma concentrations at 3 days. Started Feb 2026; status: completed.
02
Drugs
epaminurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT07374406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374406.